Journal of Pharmaceutical Innovation最新文献

筛选
英文 中文
QbD-Assisted Development and Optimization of a Finerenone Nanosuspension for Enhanced Solubility qbd辅助下制备和优化微烯酮纳米悬浮液以提高溶解度
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-29 DOI: 10.1007/s12247-026-11061-4
Ankit Mishra, Mitali Upadhyay, Meenakshi Patel
{"title":"QbD-Assisted Development and Optimization of a Finerenone Nanosuspension for Enhanced Solubility","authors":"Ankit Mishra,&nbsp;Mitali Upadhyay,&nbsp;Meenakshi Patel","doi":"10.1007/s12247-026-11061-4","DOIUrl":"10.1007/s12247-026-11061-4","url":null,"abstract":"<div><h3>Purpose</h3><p>Finerenone (FN), a selective non-steroidal mineralocorticoid receptor antagonist used for the management of kidney disease, shows poor aqueous solubility and limited oral bioavailability. The present study aimed to develop and optimize a FN-nanosuspension using Quality by Design (QbD) approach to increase its solubility.</p><h3>Methods</h3><p>FN-nanosuspension was prepared using an antisolvent precipitation method followed by high-speed homogenization and lyophilisation. The QbD design was applied by describing the Quality Target Product Profile (QTPP), categorizing Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs), and executing a risk assessment. JMP Pro 8 software was used to apply fractional factorial design for the screening of the variables and to identify the significant factors, followed by Box–Behnken Design (BBD) optimization. The prepared formulations were evaluated for particle size, PDI, zeta potential, saturation solubility, and drug content. The optimized formulation was characterized for solid-state properties (DSC, XRD, FTIR), morphology (SEM), residual solvent (GC), in vitro drug release, ex vivo intestinal permeability, and stability.</p><h3>Results</h3><p>The optimized FN-nanosuspension displayed a mean particle size of 276.6 ± 4.98 nm, acceptable zeta potential, with narrow PDI (&lt;0.3), indicating good physical stability. Saturation solubility was considerably improved compared to the pure drug. DSC, XRD, and FTIR studies confirmed the partial amorphization of the drug and no interaction between drug and excipient. The optimized nanosuspension demonstrated fast and enhanced in-vitro drug release (&gt;80% within 30 minutes) following Higuchi kinetics, along with a ~1.8-fold increase in drug diffusion by ex vivo study. Stability studies of the lyophilized formulation over six months showed no significant changes in particle size or aggregation.</p><h3>Conclusion</h3><p>The QbD-assisted development of FN-nanosuspension successfully enhanced solubility, dissolution rate, and intestinal permeability while ensuring formulation robustness and stability. The study highlights nanosuspension technology as an effective and scalable strategy to improve the oral performance of poorly soluble drugs such as FN.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computational Screening of Ziziphus Nummularia-Derived Phytochemicals: Molecular Docking & ADME Analysis For Rheumatoid Arthritis Therapy 酸枣衍生植物化学物质的计算筛选:分子对接和ADME分析治疗类风湿关节炎
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-28 DOI: 10.1007/s12247-026-11036-5
Priyanka Kaundal, Anjoo Kamboj, Hitesh Malhotra, Sandhya Jaiswal
{"title":"Computational Screening of Ziziphus Nummularia-Derived Phytochemicals: Molecular Docking & ADME Analysis For Rheumatoid Arthritis Therapy","authors":"Priyanka Kaundal,&nbsp;Anjoo Kamboj,&nbsp;Hitesh Malhotra,&nbsp;Sandhya Jaiswal","doi":"10.1007/s12247-026-11036-5","DOIUrl":"10.1007/s12247-026-11036-5","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Aim&lt;/h3&gt;&lt;p&gt;This study aimed to identify bioactive compounds for their potential as anti-arthritic drugs through virtual screening of phytochemicals from &lt;i&gt;Z. nummularia&lt;/i&gt; (ZN) to target human TLR-4, TNF-α, TCR, MMP-3 and COX-2 associated with rheumatoid arthritis.&lt;/p&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Earlier studies suggest that ZN may have immunomodulatory effects, which could potentially be relevant in autoimmune forms of arthritis. The more rigorous scientific research is needed to establish the efficacy and safety of ZN specifically for arthritis treatment.&lt;/p&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;In silico studies including Molecular docking and ADMET studies of 30 phytoconstituents obtained from ZN against selected protein target/receptors. Density Functional Theory (DFT) calculations were performed at the B3LYP/def2-SVP level to optimize molecular geometries and evaluate frontier molecular orbitals (HOMO–LUMO), electronic energy, and global reactivity descriptors of the selected phytoconstituents.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;The bioactivity scores, ADME profiles, and molecular interactions were assessed using QikProp, Molinspiration, ADMETlab 2.0, ProTox-II, and GLIDE. Molecular docking was with target receptors TLR-4 (PDB ID: 4G8E), TNF-α (PDB ID: 1A8M), T-cell receptor (PDB ID: 2AXJ), MMP-3 (PDB ID: 1G49), and COX-2 (PDB ID: 1CX2). Binding mechanisms were investigated through molecular docking studies, while protein–ligand complex stability and flexibility were further assessed using Normal Mode Analysis (NMA) through the iMODS server&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;&lt;h3&gt;Results and Conclusion&lt;/h3&gt;&lt;p&gt;Results showed that rutin-1CX2 and nummularogenin-4G8E complexes had the lowest energy scores of -9.9 kcal/mol. Nummularogenin-1G49 scored -9.8 kcal/mol, myricetin-3-O-galactoside-2AXJ scored -8.4 kcal/mol, and nummularogenin-1A8M scored -8.1 kcal/mol. These compounds exhibit drug-like properties, comply with Lipinski's rule of five, and interact with key catalytic residues, indicating their potential as anti-inflammatory drugs for rheumatoid arthritis. Both Nummularogenin and Rutin showed good binding profiles, with Nummularogenin exhibiting higher predicted affinity against several targets. Redocking the native COX-2 ligand was used to assess the docking protocol's dependability. This resulted in an RMSD of 1.278 Å, indicating an acceptable replication of the binding orientation seen in the experiment. For the purpose of comparing COX-2 binding, celecoxib was used as a reference inhibitor. Rutin and Nummularogenin underwent additional molecular dynamics (MD) simulation based on their good docking profiles, drug-like properties, and target interactions. Favourable RMSD, RMSF, Rg, and SASA profiles showed that both ligand–protein complexes had stable conformations during simulation. Overall, Nummularogenin was found to be a promising multi-target anti-inflammatory lead from &lt;i&gt;Z. nummularia&lt;/i&gt; by combined docking, validation, ADME, and MD simulation. Further biochemical, cellular, and","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-Silico Identification and Molecular Dynamics Characterization of FDA-Approved Drug Candidates Targeting MAO-B for Parkinson’s Disease Drug Repurposing fda批准的靶向MAO-B的帕金森病药物再利用候选药物的硅芯片鉴定和分子动力学表征
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-28 DOI: 10.1007/s12247-026-11072-1
Atefeh Hemmat, Ali Doostmohammadi
{"title":"In-Silico Identification and Molecular Dynamics Characterization of FDA-Approved Drug Candidates Targeting MAO-B for Parkinson’s Disease Drug Repurposing","authors":"Atefeh Hemmat,&nbsp;Ali Doostmohammadi","doi":"10.1007/s12247-026-11072-1","DOIUrl":"10.1007/s12247-026-11072-1","url":null,"abstract":"&lt;div&gt;&lt;p&gt;Parkinson’s disease (PD) is characterized by striatal dopamine depletion, a process exacerbated by upregulation of monoamine oxidase B (MAO-B), whose activity accelerates dopamine catabolism and contributes to oxidative stress. This computational study applied a knowledge-based virtual screening and drug-repurposing workflow to identify FDA-approved small molecules predicted to bind favourably to MAO-B. A curated library of 435 FDA-approved compounds with physicochemical properties compatible with blood–brain barrier permeation was screened by molecular docking against the crystal structure of human MAO-B (PDB ID: 6FW0). Rimacalib (-12.9 kcal/mol), apixaban (-12.0 kcal/mol), and roxadustat (-11.6 kcal/mol) achieved more favourable Vina docking scores than the reference inhibitor rasagiline (-9.1 kcal/mol) and were advanced to 100 ns all-atom molecular dynamics simulations. Analysis of backbone RMSD, residue RMSF, radius of gyration, solvent-accessible surface area, and principal component analysis characterized the global structural stability, flexibility, compactness, and conformational dynamics of the complexes, while hydrogen-bond occupancy analysis provided more direct evidence of sustained ligand engagement: apixaban and rimacalib maintained a persistent interaction with Thr195 for approximately 80% and over 70% of the simulation time, respectively, indicating stable positioning within the MAO-B binding pocket. MM/GBSA binding free energies ranked apixaban (-53.9 kcal/mol), rimacalib (-49.7 kcal/mol), roxadustat (-40.5 kcal/mol), and rasagiline (-20.3 kcal/mol); Phe103, Trp119, and Phe168 were identified as dominant aromatic hotspots. Beyond target engagement, apixaban and rimacalib were further prioritized based on their established clinical pharmacology, pharmacokinetic and predicted CNS-exposure profiles, and biological plausibility for PD, distinguishing them as candidates for genuine drug repurposing rather than docking-based hits alone. These findings highlight apixaban and rimacalib as predicted MAO-B-binding candidates warranting biochemical and pharmacological validation to establish their repurposing potential for PD.&lt;/p&gt;&lt;h3&gt;Graphical Abstract&lt;/h3&gt;&lt;div&gt;&lt;figure&gt;&lt;div&gt;&lt;div&gt;&lt;picture&gt;&lt;source&gt;&lt;img&gt;&lt;/source&gt;&lt;/picture&gt;&lt;/div&gt;&lt;div&gt;&lt;p&gt;Schematic representation of the computational drug repurposing pipeline for identifying potential Monoamine Oxidase B (MAO-B) inhibitors. The X-ray crystal structure of MAO-B (PDB ID: 6FW0) was obtained from the Protein Data Bank and prepared by removing water/heteroatoms and adding hydrogens to generate a ready-to-dock model. We retrieved FDA-approved compounds from DrugBank and filtered them (not withdrawn, 1.5 ≤ logP ≤ 3, MW &lt; 500 Da) to obtain 437 BBB-permeable candidates. Molecular docking identified the top five hits, followed by 100-ns molecular dynamics simulations evaluating RMSD, RMSF, Rg, SASA, hydrogen bonds, PCA, MM/GBSA, and FEL. The final selected candidates were Rimacalib, Apixaban, an","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Innovative Cheminformatics Framework Integrating Reverse Topological Indices and Machine Learning for Predictive Modeling of Myositis Therapeutics 一个整合反向拓扑指数和机器学习的创新化学信息学框架,用于肌炎治疗的预测建模
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-25 DOI: 10.1007/s12247-026-11023-w
Muhammad Waheed Rasheed, Abid Mahboob, Laiba Amin, Muhammad Amjad, Kook Cho
{"title":"An Innovative Cheminformatics Framework Integrating Reverse Topological Indices and Machine Learning for Predictive Modeling of Myositis Therapeutics","authors":"Muhammad Waheed Rasheed,&nbsp;Abid Mahboob,&nbsp;Laiba Amin,&nbsp;Muhammad Amjad,&nbsp;Kook Cho","doi":"10.1007/s12247-026-11023-w","DOIUrl":"10.1007/s12247-026-11023-w","url":null,"abstract":"<div><p>Myositis, a group of inflammatory myopathies characterized by muscle inflammation and progressive weakness, presents significant therapeutic challenges due to its complex and not fully understood pathophysiology. In this study, an innovative computational framework is proposed to investigate the molecular characteristics of drugs used in myositis treatment. Reverse degree-based topological indices, including the modified First Zagreb index, modified atom–bond connectivity index, and modified Randic index, are utilized to quantitatively describe molecular structures and capture their intrinsic properties. To enhance predictive accuracy and support pharmaceutical decision-making, advanced machine learning models, specifically Extreme Gradient Boosting (XGBoost) and Random Forest, are employed to model the relationships between topological descriptors and key physicochemical properties such as molar refractivity, molecular volume, and structural complexity. The obtained results demonstrate strong correlations, with coefficients ranging from 0.8 to 0.9, confirming the robustness of the proposed descriptors. Among the evaluated models, XGBoost demonstrated better fitting performance on the available dataset. However, given the limited sample size, these findings should be regarded as preliminary and require validation using larger datasets and independent evaluation strategies. This study contributes to pharmaceutical innovation by integrating graph-theoretical descriptors with state-of-the-art machine learning techniques to develop reliable predictive models for drug property estimation. The proposed approach offers a scalable and efficient tool for drug design optimization, supporting the advancement of precision medicine and facilitating future research in drug repurposing and therapeutic development for myositis and related disorders.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying Regulatory Bottlenecks in South Korea’s Clinical Trial Approval Process Through an Analytic Hierarchy Process Framework 通过层次分析法框架量化韩国临床试验审批过程中的监管瓶颈
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-25 DOI: 10.1007/s12247-026-11064-1
Riyan Quan, Sujata Purja, Jonghyeok Kim, Karunia Ayu Septanadhira, Eunyoung Kim
{"title":"Quantifying Regulatory Bottlenecks in South Korea’s Clinical Trial Approval Process Through an Analytic Hierarchy Process Framework","authors":"Riyan Quan,&nbsp;Sujata Purja,&nbsp;Jonghyeok Kim,&nbsp;Karunia Ayu Septanadhira,&nbsp;Eunyoung Kim","doi":"10.1007/s12247-026-11064-1","DOIUrl":"10.1007/s12247-026-11064-1","url":null,"abstract":"<div><h3>Purpose</h3><p>Drug lag is a critical issue limiting South Korea’s pharmaceutical competitiveness and patient access, and it has been linked to delays in the Investigational New Drug (IND) review process. This study aimed to identify key barriers affecting IND review efficiency in South Korea by analyzing real-world industry experience and to propose concrete strategic actions to mitigate drug lag.</p><h3>Methods</h3><p>We employed an exploratory sequential mixed-methods design. First, we used grounded theory to identify problematic factors within the IND process through semi-structured interviews. We then applied the Analytic Hierarchy Process to evaluate these factors, followed by a quadrant analysis of importance and urgency to identify top-priority tasks.</p><h3>Results</h3><p>Three core categories (rationality and patient-centricity, professional review, and operational efficiency), were identified as key domains for enhancing IND efficiency. Rationality and patient-centricity emerged as the most important and urgent criterion, followed closely by professional review. Within rationality and patient-centricity, four sub-criteria placed in the first quadrant (highly important and highly urgent): integration of patient needs into evaluation, global regulatory harmonization, acceptance of scientific evidence for new modalities, and adoption of overseas regulatory standards. Two sub-criteria within professional review (expert team review and standardized review guidelines) were also pinpointed in the first quadrant. Although operational efficiency ranked lowest, simplified Korean translation requirements stood out as the most critical factor within this category.</p><h3>Conclusion</h3><p>Transitioning from focusing on procedural speed toward embracing regulatory flexibility to enhance scientific rationality and patient access is a viable pathway for mitigating drug lag in South Korea.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic Development of Pregabalin-Loaded Intranasal Thermosensitive In Situ Gel: In-Vitro Characterization, Ex-Vivo Safety and In-Vivo Efficacy Assessment Against Partial Epilepsy 含普瑞巴林鼻内热敏原位凝胶的系统开发:体外表征、离体安全性和局部癫痫的体内疗效评估
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-24 DOI: 10.1007/s12247-026-11053-4
Tanaya D. Khairnar, Tulshidas S. Patil, Yogeeta O. Agrawal, Sameer N. Goyal, Nayan A. Gujarathi, Abhijeet A. Aher, Sanjay N. Awathale
{"title":"Systematic Development of Pregabalin-Loaded Intranasal Thermosensitive In Situ Gel: In-Vitro Characterization, Ex-Vivo Safety and In-Vivo Efficacy Assessment Against Partial Epilepsy","authors":"Tanaya D. Khairnar,&nbsp;Tulshidas S. Patil,&nbsp;Yogeeta O. Agrawal,&nbsp;Sameer N. Goyal,&nbsp;Nayan A. Gujarathi,&nbsp;Abhijeet A. Aher,&nbsp;Sanjay N. Awathale","doi":"10.1007/s12247-026-11053-4","DOIUrl":"10.1007/s12247-026-11053-4","url":null,"abstract":"<div><h3>Purpose</h3><p>To develop and optimize pregabalin-loaded thermosensitive in situ gel (PGB-loaded TS-in situ gel) for intranasal delivery to overcome PGB’s short half-life, frequent dosing, plasma-concentration fluctuations, and poor patient compliance. The study aimed to develop intranasal PGB-loaded TS-in situ gel to prolong residence time and reduce the dosing frequency by sustaining the therapeutic effects.</p><h3>Methods</h3><p>PGB-loaded TS-in situ gel was formulated using the cold technique and optimized through 3³ Box–Behnken design. It was characterized for morphology, viscosity, gel strength, gelation time, gelation temperature, and drug–polymer compatibility using X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier-transform infrared spectroscopy (FTIR). In-vitro drug release studies evaluated the release profile. Safety and tolerability were assessed through ex-vivo histopathology of sheep nasal mucosa and cell viability studies on rat nasal mucosa. In-vivo pharmacokinetics compared the intranasal formulation with oral PGB solution. Antiepileptic efficacy was evaluated using the 6-Hz psychomotor seizure model.</p><h3>Results</h3><p>The optimized formulation exhibited spherical morphology, viscosity before gelation (1220 cps), gel strength (29s), gelation time (36s), and gelation temperature of 33 °C. XRD, DSC, and FTIR confirmed molecular dispersion of PGB within the gel matrix. The formulation showed biphasic drug release, with approximately 99.82% release over 12 h. Histopathological and cell-viability studies demonstrated good nasal safety and tolerability. Pharmacokinetics showed enhanced intranasal absorption, with 1.66-fold higher Cmax, 4-fold higher Tmax, 3.35-fold higher MRT, and 5-fold higher AUC (0–∞) than the oral solution. In the 6-Hz psychomotor seizure model, the optimized formulation significantly reduced seizure characteristics associated with partial epilepsy.</p><h3>Conclusion</h3><p>The intranasal PGB-loaded TS-in situ gel provided sustained release, improved pharmacokinetic performance, and enhanced antiepileptic efficacy with nasal safety and tolerability, suggesting promising intranasal strategy for managing partial epileptic seizures. However, further clinical studies are required to confirm its efficacy and translational potential in humans.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statistical Design and Formulation of a Doxycycline-Loaded Hydrogel for Localised Periodontal Delivery Using JMP: Ex Vivo, In Vitro Antimicrobial and Safety Evaluations JMP用于局部牙周输送的多西环素负载水凝胶的统计设计和配方:体外、体外抗菌和安全性评估
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-24 DOI: 10.1007/s12247-026-11066-z
Jeevan Gowda, Deepthi V, Mallamma T, Devi Sneha M, Parimala Hanumesh, Suvetha K
{"title":"Statistical Design and Formulation of a Doxycycline-Loaded Hydrogel for Localised Periodontal Delivery Using JMP: Ex Vivo, In Vitro Antimicrobial and Safety Evaluations","authors":"Jeevan Gowda,&nbsp;Deepthi V,&nbsp;Mallamma T,&nbsp;Devi Sneha M,&nbsp;Parimala Hanumesh,&nbsp;Suvetha K","doi":"10.1007/s12247-026-11066-z","DOIUrl":"10.1007/s12247-026-11066-z","url":null,"abstract":"<div><h3>Purpose</h3><p>Periodontitis requires localized therapy that controls infection while maintaining periodontal tissue compatibility. This study aimed to develop and optimize a doxycycline hydrochloride (Dox-HCl)-loaded hydrogel using a Design of Experiments approach.</p><h3>Methods</h3><p>A β-cyclodextrin (β-CD), sodium alginate (SA), and polyvinyl alcohol (PVA) hydrogel was optimized using a three-factor, three-level Box–Behnken design in JMP. The optimized F4 formulation was evaluated for physicochemical properties, syringeability, drug content, drug release, mucoadhesion, cytocompatibility, antimicrobial activity against <i>Porphyromonas gingivalis</i>, and CAM vascular responses.</p><h3>Results</h3><p>F4 showed a pH of ~ 6.8, shear-dependent viscosity, acceptable syringeability through a 25-gauge needle, and ~ 98.5% drug content. FTIR and DSC supported characterization of the Dox-HCl–excipient mixture, although final hydrogel compatibility and Dox-HCl/β-CD inclusion-complex formation were not definitively established. Approximately 94% drug release occurred within 240 min, following anomalous transport (Korsmeyer–Peppas <i>n</i> = 0.63). F4 showed concentration-dependent antimicrobial activity, with MIC and MBC values of 7.8 and 15.6 µg/mL, respectively. A 17 mm inhibition zone was observed against <i>P. gingivalis</i>, while L929 cell viability remained &gt; 90%. HET-CAM analysis showed differences in selected vascular parameters between F4 and blank-hydrogel-treated CAMs.</p><h3>Conclusion</h3><p>F4 demonstrated favourable physicochemical properties with preliminary antimicrobial, cytocompatibility, release, mucoadhesive, and CAM responses, supporting its potential as a localized Dox-HCl delivery platform. Further studies addressing drug retention, periodontal-specific compatibility, polymicrobial biofilms, stability, vascular responses, and in vivo efficacy are required.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering the Mucosal Frontier: Nanotechnology-Enabled Transmucosal Drug Delivery System in Emerging Era 工程粘膜前沿:纳米技术在新兴时代的跨粘膜给药系统
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-24 DOI: 10.1007/s12247-026-11041-8
Rasmita Nayak, Ridhima Sandal, Mahika Yaduvanshi, Sandhya Verma, Sanjula Baboota, Nupur Shrivastava
{"title":"Engineering the Mucosal Frontier: Nanotechnology-Enabled Transmucosal Drug Delivery System in Emerging Era","authors":"Rasmita Nayak,&nbsp;Ridhima Sandal,&nbsp;Mahika Yaduvanshi,&nbsp;Sandhya Verma,&nbsp;Sanjula Baboota,&nbsp;Nupur Shrivastava","doi":"10.1007/s12247-026-11041-8","DOIUrl":"10.1007/s12247-026-11041-8","url":null,"abstract":"<div><h3>Introduction</h3><p>Transmucosal drug delivery systems (TM-DDS) have transformed pharmaceutical sciences from 2020 to the present by utilising vascularised mucosal surfaces, including buccal, nasal, sublingual, vaginal, rectal, and ocular channels, thereby surmounting the restrictions associated with oral and parenteral administration. These needle-free platforms circumvent first-pass metabolism, resulting in significant enhancements in bioavailability, a swift therapeutic start, and improved patient compliance, particularly among paediatric and geriatric populations resistant to injections. This review emphasises that mucosal absorption occurs through paracellular channels and transcellular pathways across epithelial membranes, hindered by route-specific obstacles. The personalised treatments incorporate nanotechnology-integrated polymeric nanoparticles, liposomes, and dendrimers, enabling precise, controlled release and targeting the disease. The analysis illustrates that the clinical pipelines encompass endocrinology, cardiovascular disorders, oncology, and specific demographics, with market forecasts predicting buccal systems will attain USD 3.91 billion by 2027. </p><h3>Methodology</h3><p>This review aims to collect, analyse, and summarise information from already published research articles and reviews related to the transmucosal drug delivery system that were collected from various sources such as Google Scholar, PubMed, and ScienceDirect. Therefore, there is no need for ethical authorisation. The collective information was evaluated and synthesised to provide an overview of recent advances, challenges, and future perspectives in transmucosal drug delivery systems.</p><h3>Conclusion</h3><p>The TM-DDS demonstrates superior formulation stability, scalable production, less inter-patient variability, and compliance with FDA/EMA regulations. Emerging safer alternatives like intelligent biomaterials, personalised 3D printing, and enhanced pipelines promise accessible, patient-centred medicines that will improve efficacy, adherence, and global health outcomes in the future years. </p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing Antidiabetic Potential of Navayasa Churnam: Phyto-Metabolomics, Systems Pharmacology, In Vitro, In Vivo, and In Silico Studies 建立Navayasa Churnam的降糖潜力:植物代谢组学,系统药理学,体外,体内和计算机研究
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-24 DOI: 10.1007/s12247-026-11060-5
Sibu Sen, Faizan Momin, Kalpana Talari, Ezhilmathe A., Nabarun Mukhopadhyay, Poornima S., Chandraiah Godugu, Venkata Rao Kaki, Manoj P. Dandekar, Amol G. Dikundwar
{"title":"Establishing Antidiabetic Potential of Navayasa Churnam: Phyto-Metabolomics, Systems Pharmacology, In Vitro, In Vivo, and In Silico Studies","authors":"Sibu Sen,&nbsp;Faizan Momin,&nbsp;Kalpana Talari,&nbsp;Ezhilmathe A.,&nbsp;Nabarun Mukhopadhyay,&nbsp;Poornima S.,&nbsp;Chandraiah Godugu,&nbsp;Venkata Rao Kaki,&nbsp;Manoj P. Dandekar,&nbsp;Amol G. Dikundwar","doi":"10.1007/s12247-026-11060-5","DOIUrl":"10.1007/s12247-026-11060-5","url":null,"abstract":"<div><h3>Purpose</h3><p>Navayasa Churnam (NVC) is a traditional Ayurvedic polyherbal preparation that contains nine medicinal plants as well as elemental iron, commonly used for the treatment of variety of disease conditions including metabolic disorders. The present study aims to explore NVC's phytochemical composition and molecular processes underlying its potential antidiabetic effects. </p><h3>Methods</h3><p>This study evaluated NVC’s antidiabetic potential using an integrated techniques that included LC-Orbitrap HRMS/MS-based phyto-metabolomics, network pharmacology, molecular docking, in vitro, and in vivo validation. </p><h3>Results</h3><p>Untargeted LC-MS/MS profiling yielded a preliminary identification of 129 phytoconstituents spanning across flavonoids, alkaloids, phenolic acids, and terpenoids. NVC exhibited inhibitory effect towards α-glucosidase with an IC<sub>50</sub> value of 21.47 ± 1.55 µg/mL. NVC administration boosted glucose intake in HepG2 cells under hyperglycemic and lipotoxic circumstances compared to the disease control, with an effect similar to metformin. NVC therapy significantly reduced fasting blood glucose levels by approximately 62% in STZ-induced diabetic rats compared to disease control (<i>p</i> &lt; 0.0001). NVC treatment increased hepatic GLUT4 levels from 6.5 to 8.5 ng/mg, suggesting partial restoration of GLUT4 expression (<i>p</i> &lt; 0.05). </p><h3>Conclusions</h3><p>Network pharmacology identified 12 hub proteins involved in glucose metabolism, insulin signaling, and oxidative stress, and molecular docking demonstrated favorable interactions between NVC phytoconstituents and diabetes-related targets. Collectively, these findings provide quantified experimental and computational data supporting NVC formulation’s multi-targeted antidiabetic potential.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality by Design-Driven Development and Optimization of Anti-Rheumatic Solid Lipid Nanoparticles-Loaded Hydrogel: Formulation Characterization, Rheological Evaluation, and Preclinical Efficacy 抗风湿病固体脂质纳米颗粒负载水凝胶的设计驱动开发和优化:配方表征,流变学评估和临床前疗效
IF 2.6 4区 医学
Journal of Pharmaceutical Innovation Pub Date : 2026-09-24 DOI: 10.1007/s12247-026-11074-z
Prajakta Pujari, Meenaxi Maste, Preeti Salve
{"title":"Quality by Design-Driven Development and Optimization of Anti-Rheumatic Solid Lipid Nanoparticles-Loaded Hydrogel: Formulation Characterization, Rheological Evaluation, and Preclinical Efficacy","authors":"Prajakta Pujari,&nbsp;Meenaxi Maste,&nbsp;Preeti Salve","doi":"10.1007/s12247-026-11074-z","DOIUrl":"10.1007/s12247-026-11074-z","url":null,"abstract":"<div><h3>Purpose</h3><p>Rheumatoid arthritis is a chronic autoimmune disease requiring long-term therapy, often limited by systemic adverse effects and inadequate drug delivery to inflamed joints. This study aimed to develop and optimize a ferulic acid-loaded solid lipid nanoparticle hydrogel using a Quality-by-Design approach to improve topical anti-arthritic therapy.</p><h3>Methods</h3><p>Nanoparticles were prepared by hot-homogenization and optimized using a Box-Behnken design. The optimized nanoparticles were characterized by dynamic light scattering, zeta potential, scanning and transmission electron microscopy, followed by in-vitro evaluation and incorporation into a xanthan gum-based gel. The hydrogel was further assessed for physicochemical properties, stability, in-vitro drug release, ex-vivo skin permeation, dermal safety, anti-inflammatory activity using the carrageenan-induced paw edema model, and anti-arthritic efficacy in the complete Freund’s adjuvant-induced arthritis model.</p><h3>Results</h3><p>The optimized nanoparticles exhibited a favourable in-vitro safety profile with 95.6 ± 0.4% cell viability, significantly inhibited protein denaturation (74.3 ± 0.2%), and effectively suppressed COX-2 activity (IC₅₀ = 40.86 µg/ml). The hydrogel demonstrated desirable physicochemical properties, excellent stability, and sustained drug release, achieving 83.2 ± 0.3% cumulative drug release and 72.9 ± 0.4% ex-vivo skin permeation after 8 h. In vivo studies showed superior anti-inflammatory and anti-arthritic efficacy compared with the conventional gel, as evidenced by significant reductions in paw edema, preservation of body weight, and marked protection against cartilage and bone damage.</p><h3>Conclusion</h3><p>The Quality-by-Design optimized ferulic acid loaded solid lipid nanoparticles-based hydrogel is a promising topical drug delivery system for rheumatoid arthritis, offering sustained release, enhanced dermal permeation, and improved local therapeutic efficacy.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书